Anthera Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 21,684 49,219 85,281 29,457
Sales, General and Admin. 6,563 6,715 7,857 6,301
Non-Recurring Items - - - -
Other - - - -
Operating Income (28,247) (55,934) (93,138) (35,758)
Income From Continuing Operations
Add'l Income/Expense Items (15) 13,959 (3,132) (3,811)
Earnings Before Interest and Tax (28,262) (41,975) (96,270) (39,569)
Interest Expense 2,599 3,354 2,803 845
Earnings Before Tax (30,861) (45,329) (99,073) (40,414)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (30,861) (45,329) (99,073) (40,414)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (30,861) (45,329) (99,073) (40,414)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (30,861) (45,329) (99,073) (40,414)